较小剂量柔红霉素诱导老年急性髓细胞白血病临床观察
 |
| 第1页 |
参见附件(3155KB，3页)。
[摘要] 目的：探讨较小剂量柔红霉素(DNR)诱导老年急性髓细胞白血病(AML)缓解的临床疗效。方法：将80例老年AML患者随机分为治疗组(40例)和对照组(40例)，两组患者均采用DA化疗方案，治疗组患者柔红霉素采用较小剂量30 mg/(m2·d)，对照组患者柔红霉素采用标准剂量45 mg/(m2·d)，随访2个疗程，比较两组患者的临床疗效和Ⅲ度以上骨髓抑制、感染、胃肠道反应等药物不良反应。结果：治疗组患者完全缓解16例，缓解率为40%，对照组患者完全缓解18例，缓解率为45%，两组患者完全缓解率比较差异无统计学意义(P>0.05)；治疗组患者不良反应11例，占28%，对照组患者不良反应18例，占45%，对照组不良反应发生率明显高于治疗组，两组患者比较差异有统计学意义(P<0.05)。结论：较小剂量柔红霉素诱导老年AML，疗效满意，药物不良反应少，值得临床推广。
[关键词] 柔红霉素；较小剂量；老年髓性白血病；临床疗效
[中图分类号] R733.71 [文献标识码]A[文章编号]1674-4721(2011)07(a)-012-02
Small dose of daunorubicin induced acute myeloid leukemia observed
LIU Huayu, XIANG Hongju
People′s Hospital of Sangzhi County, Hunan Province, Sangzhi427100, China
[Abstract] Objective: To investigate the small dose of daunorubicin (DNR) induced acute myeloid leukemia (AML) remission of clinical efficacy. Methods: 80 cases of elderly AML patients were randomly divided into treatment group (40 cases) and control group (40 cases), two groups of patients were treated with DA chemotherapy, patients treated with smaller doses of daunorubicin 30 mg/(m2·d), control group of patients with standard doses of daunorubicin 45 mg/(m2·d), followed 2 courses of treatment were compared the clinical efficacy and Ⅲ degrees of bone marrow suppression, infections, gastrointestinal reactions and other adverse drug reactions. Results: The patients with complete remission in 16 cases, remission rate of 40% in the control group were complete remission in 18 cases, 45% response rate, complete remission rate between the two groups were not significantly different (P>0.05); treatment of poor patients reaction in 11 cases, accounting for 28% in the control group were adverse events in 18 cases, 45% in the control group rate of adverse events was significantly higher than the treatment group, two groups were statistically significant differences (P<0.05). Conclusion: The low dose of daunorubicin induced elderly AML, satisfactory outcome, adverse drug reaction is little worthy to be popularized.
[Key words] Daunorubicin; Smaller doses; Old myeloid leukemia; Clinical efficacy ......
您现在查看是摘要介绍页，详见PDF附件(3155KB，3页)。